Frontiers

Up Front Winter 2013

Understanding the Molecular Mechanisms of Malignancy is Key to Cancer Care A tenet of Ohio State's cancer program is that there is no such thing as a routine cancer. Likewise, there is nothing routine about the science-based care we offer. ...[Read more]
Published: Feb-13-13 | 1  Comment | 0  Link to this post

Frontline Winter 2013

Recurrent Ovarian Cancer: WE MUST DO BETTER Ovarian cancer is a relatively rare disease, but it is the most lethal of all gynecologic malignancies and the fifth most common cause of cancer death in women. About 22,300 women were expected to be ...[Read more]
Published: Feb-13-13 | 1  Comment | 0  Link to this post

Break Through Winter 2013

HEDGEHOG HUNTING A Possible Therapy for Tamoxifen-Resistant Breast Cancer BHUVANESWARI RAMASWAMY, MD, a medical oncologist specializing in breast cancer at the OSUCCC - JamesSARMILA MAJUMDER, PHD, a research assistant professor in ...[Read more]
Published: Feb-13-13 | 0  Comment | 0  Link to this post

Of Note Winter 2013

AWARDS AND HONORS JOHN C.BYRD, MD, was featured in Clinical Cancer Advances 2012: ASCO’s Annual Report on Progress Against Cancer. Published by the American Society of Clinical Oncology, the annual report i ...[Read more]
Published: Feb-13-13 | 1  Comment | 0  Link to this post

About-Face for Chronic Leukemia

Origin of CLL and the Molecular Mechanism of Ibrutinib Multipotent hematopoietic stem cells (HSC) give rise to healthy B lymphocytes. Recent evidence suggests that genetic changes at the HSC level lead to monoclonal B cells that the ...[Read more]
Published: Feb-13-13 | 0  Comment | 0  Link to this post

A Singular Focus on Lung Cancer

DAVID CARBONE, MD, PHD, lung cancer specialist for the OSUCCC - James A Singular Focus On Lung Cancer David Carbone joins Ohio State's lung cancer team to organize a thoracic oncology center By BOB HECKER David Carbone, MD, PhD, ...[Read more]
Published: Feb-13-13 | 0  Comment | 0  Link to this post

Mechanisms of Resilience

  Shown in one of the seven “vaults” that will house linear accelerators on the second floor of the new James Cancer Hospital and Solove Research Institute are (from left): Erica Hlavin Bell, PhD, research as ...[Read more]
Published: Feb-13-13 | 0  Comment | 0  Link to this post

Bench to Bedside Winter 2013

Phase II study of lenalidomide to repair immune synapse response and humoral immunity in early-stage, asymptomatic chronic lymphocytic leukemia/small lymphocytic lymphoma (CLL/SLL) with high-risk genomic features HYPOTHESIS: Low-dose lenalidomi ...[Read more]
Published: Feb-13-13 | 0  Comment | 0  Link to this post

 Next >>